AGP Picks
View all

Paxman expands beyond scalp cooling with neuropathy device launch

Nov. 5, 2026
Paxman expands beyond scalp cooling with neuropathy device launch
By AI, Created 08:27 UTC, Nov 05, 2026, AGP -

Paxman has launched its Paxman Neuropathy System in several European markets, extending the company beyond scalp cooling into prevention of chemotherapy-induced peripheral neuropathy. The rollout follows new clinical data and comes as the treatment remains a major unmet need in oncology.

Why it matters: - Chemotherapy-induced peripheral neuropathy can cause numbness, pain, tingling and loss of sensation in the hands and feet. - The condition can disrupt daily life and, in some cases, force chemotherapy dose reductions, delays or discontinuation. - Paxman is moving beyond scalp cooling and into another major side effect area in oncology. - The launch adds a new option in a field with no established standard preventive treatment.

What happened: - Paxman announced the commercial launch of the Paxman Neuropathy System on Nov. 5, 2026. - The device is a cryocompression system designed to help reduce the risk and severity of chemotherapy-induced peripheral neuropathy, or CIPN. - The launch marks Paxman’s first major product expansion beyond scalp cooling for chemotherapy-induced hair loss. - The system is launching in the U.K., France, Germany, the Netherlands, Spain and Italy after recent regulatory approvals. - Pilot programs are already underway in the U.K., with broader rollout planned across Europe in the coming months.

The details: - Paxman has been a global leader in scalp cooling for more than 25 years. - The company expanded its portfolio after acquiring Dignitana in 2025. - CIPN affects millions of cancer patients worldwide each year. - Symptoms can make walking, writing, dressing and sleeping difficult. - Symptoms can persist long after treatment ends. - The device launch coincides with clinical data published in JCO Oncology Advances from a prospective multicenter phase I/II study. - That study evaluated the Paxman Neuropathy System in patients receiving taxane-based chemotherapy. - The study found the device was safe, well tolerated and associated with low rates of CIPN. - Among 146 evaluable patients, no one developed severe neuropathy. - Patient-reported clinically significant sensory symptoms remained low throughout follow-up. - The launch also coincides with a scientific review in Therapeutic Advances in Medical Oncology that examines CIPN causes, impact and possible prevention strategies. - The review identified cryotherapy and cryocompression among the most promising emerging interventions.

Between the lines: - Paxman is trying to translate its scalp cooling expertise into a broader oncology supportive-care platform. - The timing suggests the company is using published data to support commercial adoption in Europe. - Ongoing studies in the U.S. and at Dana-Farber Cancer Institute point to further evidence generation around the technology. - The clinical focus is important because CIPN can affect treatment tolerance and quality of life at the same time.

What's next: - Paxman plans to expand the European pilot programs to additional centers over the next few months. - The SWOG S2205 ICE COMPRESS randomized study is ongoing in the U.S. - An additional clinical trial at Dana-Farber Cancer Institute is also evaluating the Paxman Neuropathy System. - More data from these studies could shape future adoption in oncology care.

The bottom line: - Paxman is betting that cryocompression can become a second major business line by addressing one of oncology’s most persistent unmet needs.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

The Madrid Wire

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The Madrid Wire

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.